<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE pdf2xml SYSTEM "pdf2xml.dtd">

<pdf2xml producer="poppler" version="23.12.0">
<page number="1" position="absolute" top="0" left="0" height="793" width="595">
	<fontspec id="0" size="10" family="GIIPEA+BrpnwyAdvTT86d47313" color="#1b1b18"/>
	<fontspec id="1" size="10" family="GIIPFB+XyygrkAdvTT86d47313+20" color="#1b1b18"/>
	<fontspec id="2" size="10" family="GIEMFE+XhwqkqAdvTTaf7f9f4f.B" color="#1b1b18"/>
	<fontspec id="3" size="10" family="GIIPKP+BfrpnpAdvTT86d47313+22" color="#1b1b18"/>
	<fontspec id="4" size="10" family="GIIPLA+DchcghAdvTT86d47313+03" color="#1b1b18"/>
	<fontspec id="5" size="9" family="GIEMNE+GbxpbkAdvTT99c4c969" color="#1b1b18"/>
	<fontspec id="6" size="10" family="GIIPMB+HxjgtxAdvTT8861b38f.I" color="#1b1b18"/>
	<fontspec id="7" size="9" family="GIEMFE+XhwqkqAdvTTaf7f9f4f.B" color="#1b1b18"/>
	<fontspec id="8" size="9" family="GIEMND+HhfbdsAdvTTb5929f4c" color="#1b1b18"/>
	<fontspec id="9" size="8" family="GIEMND+HhfbdsAdvTTb5929f4c" color="#000000"/>
	<fontspec id="10" size="8" family="GIEMMC+TpsvbyAdvTTe45e47d2" color="#1b1b18"/>
	<fontspec id="11" size="8" family="GIIOPA+BhxgtnAdvTT7329fd89.I" color="#1b1b18"/>
	<fontspec id="12" size="8" family="MyriadPro" color="#1b1b18"/>
<text top="90" left="57" width="234" height="9" font="0">characteristics included anatomic cancer site, anatomic</text>
<text top="102" left="57" width="234" height="9" font="0">cancer subsite, stage, grade, histology and p16 staining</text>
<text top="114" left="57" width="234" height="9" font="0">(the most commonly used surrogate marker for HPV sta-</text>
<text top="126" left="57" width="234" height="9" font="0">tus) [<a href="">23</a>]. Testing for p16 was performed routinely on pri-</text>
<text top="138" left="57" width="234" height="9" font="0">maries of the base of tongue and tonsillar region and at</text>
<text top="150" left="57" width="98" height="9" font="0">the surgeon/pathologist</text>
<text top="147" left="155" width="2" height="13" font="1">’</text>
<text top="150" left="156" width="134" height="9" font="0">s discretion otherwise. Primary</text>
<text top="162" left="57" width="234" height="9" font="0">treatment details (treatment within the first 5 months of</text>
<text top="174" left="57" width="234" height="9" font="0">therapy initiation) and outcomes, including recurrence</text>
<text top="186" left="57" width="234" height="9" font="0">rates and survival within the follow- up period were also</text>
<text top="198" left="57" width="234" height="9" font="0">collected, with follow-up defined as the last clinical</text>
<text top="210" left="57" width="234" height="9" font="0">encounter prior to September 2013. Patients were de-</text>
<text top="222" left="57" width="234" height="9" font="0">identified and data was entered into a database on a</text>
<text top="234" left="57" width="122" height="9" font="0">password-protected computer.</text>
<text top="266" left="57" width="85" height="9" font="2">Statistical analysis</text>
<text top="279" left="57" width="234" height="9" font="0">The two types of HNC were compared using chi-square</text>
<text top="291" left="57" width="234" height="9" font="0">tests for dichotomous categorical variables or Fishers exact</text>
<text top="303" left="57" width="234" height="9" font="0">test where appropriate. Wald test was used to compare</text>
<text top="315" left="57" width="234" height="9" font="0">variables with 3 categories. Continuous variables were</text>
<text top="327" left="57" width="234" height="9" font="0">compared using the non-parametric Wilcoxon test. The</text>
<text top="339" left="57" width="234" height="9" font="0">primary outcome was disease-free survival defined as sur-</text>
<text top="351" left="57" width="234" height="9" font="0">vival free of relapse. Death was treated as a competing risk</text>
<text top="363" left="57" width="234" height="9" font="0">and reported as relapse-free mortality. Data was censored</text>
<text top="375" left="57" width="234" height="9" font="0">on date of last known follow-up. Overall survival was ana-</text>
<text top="387" left="57" width="234" height="9" font="0">lyzed as a secondary outcome. All events were measured</text>
<text top="399" left="57" width="142" height="9" font="0">from the date of diagnosis. Gray</text>
<text top="396" left="199" width="2" height="13" font="1">’</text>
<text top="399" left="200" width="90" height="9" font="0">s test for equality of</text>
<text top="411" left="57" width="234" height="9" font="0">cumulative incidence functions was used to assess differ-</text>
<text top="423" left="57" width="234" height="9" font="0">ences between types of HNC. The cumulative incidence of</text>
<text top="435" left="57" width="234" height="9" font="0">mortality in the presence of relapse was also modeled.</text>
<text top="447" left="57" width="234" height="9" font="0">Cumulative incidence looks at the probability of relapse</text>
<text top="459" left="57" width="234" height="9" font="0">conditional on relapse free survival and competing risk for</text>
<text top="471" left="57" width="153" height="9" font="0">survival adjusting for the risk of death.</text>
<text top="483" left="65" width="226" height="9" font="0">The proportional hazards model for subdistribution</text>
<text top="495" left="57" width="234" height="9" font="0">was used to model the cumulative incidence of relapse</text>
<text top="507" left="57" width="234" height="9" font="0">and relapse-free mortality <a href="">[25]. </a>Univariate competing</text>
<text top="519" left="57" width="234" height="9" font="0">risk regression models were performed to look at type of</text>
<text top="531" left="57" width="234" height="9" font="0">HNC. Multivariate models were used adjusting for</text>
<text top="543" left="57" width="234" height="9" font="0">COPD, age, overall stage, treatment and previous malig-</text>
<text top="555" left="57" width="234" height="9" font="0">nancy. Linearity of continuous variables and propor-</text>
<text top="567" left="57" width="234" height="9" font="0">tional hazards assumption of categorical variables was</text>
<text top="579" left="57" width="234" height="9" font="0">tested. Age violated assumptions of linearity and was</text>
<text top="591" left="57" width="158" height="9" font="0">therefore modeled as age &lt; 55 vs. age</text>
<text top="588" left="217" width="5" height="13" font="3">≥</text>
<text top="591" left="224" width="66" height="9" font="0">55. Overall sur-</text>
<text top="603" left="57" width="234" height="9" font="0">vival was characterized using Kaplan-Meier plots and</text>
<text top="615" left="57" width="234" height="9" font="0">the Log-rank test was used to compare type of HNC.</text>
<text top="627" left="57" width="234" height="9" font="0">Cox-proportional hazards model was used to estimate</text>
<text top="639" left="57" width="195" height="9" font="0">hazard ratios. Level of significance was set at</text>
<text top="636" left="256" width="5" height="13" font="4">α</text>
<text top="639" left="264" width="27" height="9" font="0">= 0.05.</text>
<text top="651" left="57" width="234" height="9" font="0">SAS STAT software v9.3 (Cary, NC: SAS Institute Inc.)</text>
<text top="663" left="57" width="102" height="9" font="0">was used for all analyses.</text>
<text top="689" left="57" width="33" height="9" font="2">Results</text>
<text top="702" left="57" width="111" height="8" font="5">Primary subsite distribution</text>
<text top="714" left="57" width="234" height="9" font="0">There were 582 charts reviewed with 318 (55 %) pa-</text>
<text top="726" left="57" width="234" height="9" font="0">tients meeting the inclusion criteria. Of those analyzed,</text>
<text top="90" left="305" width="234" height="9" font="0">122 (38 %) had been diagnosed with OPSCC and 196</text>
<text top="102" left="305" width="234" height="9" font="0">(62 %) patients had other HNSCC primaries (Table <a href="">1</a>).</text>
<text top="114" left="305" width="234" height="9" font="0">Analysis was performed on all available data. However,</text>
<text top="126" left="305" width="234" height="9" font="0">there were varying levels of availability in patient charts</text>
<text top="138" left="305" width="234" height="9" font="0">as demonstrated by the variability in sample sizes for</text>
<text top="150" left="305" width="89" height="9" font="0">specific comparisons.</text>
<text top="187" left="305" width="182" height="8" font="5">Demographics, risk factors and comorbidities</text>
<text top="198" left="305" width="33" height="9" font="0">Patients</text>
<text top="196" left="337" width="2" height="13" font="1">’</text>
<text top="198" left="345" width="194" height="9" font="0">demographics, risk factors and comorbidities</text>
<text top="210" left="305" width="234" height="9" font="0">are reported in Table <a href="">2. </a>There were no significant differ-</text>
<text top="222" left="305" width="234" height="9" font="0">ences in smoking history between patients with OPSCC</text>
<text top="234" left="305" width="131" height="9" font="0">and other types of HNC (</text>
<text top="232" left="436" width="13" height="13" font="6">n =</text>
<text top="234" left="451" width="87" height="9" font="0">312, never smoked</text>
<text top="246" left="305" width="234" height="9" font="0">21(17 %) vs 25(13 %), current smoker 48(39 %) vs 91(46 %)</text>
<text top="258" left="305" width="165" height="9" font="0">and quit smoking 53(43 %) vs 74(38 %),</text>
<text top="256" left="474" width="5" height="13" font="6">p</text>
<text top="258" left="480" width="58" height="9" font="0">= 0.3002). The</text>
<text top="270" left="305" width="234" height="9" font="0">same was shown when pack year history was analyzed</text>
<text top="282" left="305" width="161" height="9" font="0">(Current smokers: 41.5 % vs 44.09 %</text>
<text top="280" left="471" width="5" height="13" font="6">p</text>
<text top="282" left="478" width="61" height="9" font="0">= 0.9891; Quit</text>
<text top="294" left="305" width="129" height="9" font="0">smoking: 27.79 % vs 32.18 %,</text>
<text top="292" left="438" width="5" height="13" font="6">p</text>
<text top="294" left="445" width="93" height="9" font="0">= 0.2969). Those with</text>
<text top="306" left="305" width="234" height="9" font="0">OPSCC, however, were significantly less likely to have</text>
<text top="318" left="305" width="133" height="9" font="0">COPD as a co-morbidity (</text>
<text top="316" left="438" width="13" height="13" font="6">n =</text>
<text top="318" left="453" width="86" height="9" font="0">318, 19(16 %) vs</text>
<text top="330" left="305" width="39" height="9" font="0">53(27 %),</text>
<text top="328" left="347" width="5" height="13" font="6">p</text>
<text top="330" left="354" width="185" height="9" font="0">= 0.0175). Particularly of note there were no</text>
<text top="342" left="305" width="234" height="9" font="0">significant differences in patients diagnosed at age &lt;55 years</text>
<text top="354" left="305" width="3" height="9" font="0">(</text>
<text top="352" left="308" width="13" height="13" font="6">n =</text>
<text top="354" left="323" width="215" height="9" font="0">316, 91(75 %)) compared to those age 55 years</text>
<text top="366" left="305" width="98" height="9" font="0">and older (147(75 %),</text>
<text top="364" left="408" width="5" height="13" font="6">p</text>
<text top="366" left="415" width="124" height="9" font="0">= 0.8123), in patient gender</text>
<text top="378" left="305" width="3" height="9" font="0">(</text>
<text top="376" left="308" width="13" height="13" font="6">n =</text>
<text top="378" left="323" width="151" height="9" font="0">318, males: 97(80 %) vs. 140(71 %),</text>
<text top="376" left="478" width="5" height="13" font="6">p</text>
<text top="378" left="486" width="53" height="9" font="0">= 0.1078), in</text>
<text top="390" left="305" width="66" height="9" font="0">marijuana use (</text>
<text top="388" left="371" width="13" height="13" font="6">n =</text>
<text top="390" left="386" width="103" height="9" font="0">128, 10(8 %) vs 17(9 %),</text>
<text top="388" left="492" width="5" height="13" font="6">p</text>
<text top="390" left="500" width="39" height="9" font="0">= 0.8267)</text>
<text top="402" left="305" width="99" height="9" font="0">or in drinking status (</text>
<text top="400" left="404" width="13" height="13" font="6">n =</text>
<text top="402" left="419" width="120" height="9" font="0">267, never drank 4(3 %) vs</text>
<text top="414" left="305" width="234" height="9" font="0">8(4 %), current drinker 84(69 %) vs 126(64 %) and quit</text>
<text top="426" left="305" width="131" height="9" font="0">drinking 20(16 %) vs 25(13 %),</text>
<text top="424" left="440" width="5" height="13" font="6">p</text>
<text top="426" left="447" width="92" height="9" font="0">= 0.7538). Finally, the</text>
<text top="438" left="305" width="234" height="9" font="0">Charlson probability for 10 year survival demonstrated</text>
<text top="450" left="305" width="113" height="9" font="0">no significant difference (</text>
<text top="448" left="418" width="13" height="13" font="6">n =</text>
<text top="450" left="434" width="105" height="9" font="0">318, &gt;50 % 89(28 %) vs</text>
<text top="462" left="305" width="44" height="9" font="0">140(44 %),</text>
<text top="460" left="352" width="5" height="13" font="6">p</text>
<text top="462" left="359" width="41" height="9" font="0">= 0.7984).</text>
<text top="498" left="305" width="107" height="8" font="5">Treatment and weight loss</text>
<text top="510" left="305" width="234" height="9" font="0">Treatment and weight loss data is summarized in</text>
<text top="522" left="305" width="234" height="9" font="0">Table <a href="">3. </a>These comparisons demonstrated that OPSCCs</text>
<text top="534" left="305" width="234" height="9" font="0">were more likely to be given combination therapy, in-</text>
<text top="546" left="305" width="30" height="9" font="0">cluding</text>
<text top="543" left="338" width="4" height="13" font="1">“</text>
<text top="546" left="342" width="123" height="9" font="0">surgery and radiation therapy</text>
<text top="543" left="465" width="4" height="13" font="1">”</text>
<text top="546" left="472" width="30" height="9" font="0">(S-RT),</text>
<text top="543" left="505" width="4" height="13" font="1">“</text>
<text top="546" left="509" width="30" height="9" font="0">surgery</text>
<text top="586" left="305" width="30" height="8" font="7">Table 1</text>
<text top="586" left="337" width="180" height="8" font="8">Anatomical subsite distribution of HNSCC primary</text>
<text top="597" left="305" width="30" height="8" font="8">tumours</text>
<text top="611" left="305" width="12" height="7" font="9">Site</text>
<text top="611" left="415" width="44" height="7" font="9">Frequency (n)</text>
<text top="611" left="514" width="24" height="7" font="9">Percent</text>
<text top="624" left="305" width="38" height="7" font="9">Oropharynx</text>
<text top="624" left="415" width="11" height="7" font="9">122</text>
<text top="624" left="514" width="21" height="7" font="9">38.4 %</text>
<text top="638" left="305" width="53" height="7" font="9">Lip &amp; Oral Cavity</text>
<text top="638" left="415" width="8" height="7" font="9">86</text>
<text top="638" left="514" width="21" height="7" font="9">27.0 %</text>
<text top="652" left="305" width="21" height="7" font="9">Larynx</text>
<text top="652" left="415" width="8" height="7" font="9">72</text>
<text top="652" left="514" width="21" height="7" font="9">22.6 %</text>
<text top="666" left="305" width="43" height="7" font="9">Hypopharynx</text>
<text top="666" left="415" width="8" height="7" font="9">15</text>
<text top="666" left="514" width="17" height="7" font="9">4.7 %</text>
<text top="680" left="305" width="41" height="7" font="9">Nasopharynx</text>
<text top="680" left="415" width="8" height="7" font="9">10</text>
<text top="680" left="514" width="17" height="7" font="9">3.1 %</text>
<text top="694" left="305" width="38" height="7" font="9">Nasal Cavity</text>
<text top="694" left="415" width="4" height="7" font="9">8</text>
<text top="694" left="514" width="17" height="7" font="9">2.5 %</text>
<text top="708" left="305" width="55" height="7" font="9">Paranasal Sinuses</text>
<text top="708" left="415" width="4" height="7" font="9">4</text>
<text top="708" left="514" width="17" height="7" font="9">1.3 %</text>
<text top="722" left="305" width="48" height="7" font="9">Salivary Glands</text>
<text top="722" left="415" width="4" height="7" font="9">1</text>
<text top="722" left="514" width="17" height="7" font="9">0.3 %</text>
<text top="35" left="57" width="23" height="7" font="10">Murray</text>
<text top="35" left="83" width="187" height="7" font="11">et al. Journal of Otolaryngology - Head and Neck Surgery</text>
<text top="33" left="272" width="44" height="9" font="12"> (2015) 44:30 </text>
<text top="35" left="496" width="43" height="7" font="10">Page 3 of 11</text>
</page>
</pdf2xml>
